Table 2.
Mean urinary (±SD) concentrations of ten biomarkers assessed by ELISA in cohort of 288 subjects
| Biomarker | Total bladder cancer | Low-grade bladder cancer | High-grade bladder cancer | NMIBC | MIBC | Controls |
|---|---|---|---|---|---|---|
| (75.9 %) | (41.2 %) | (58.8 %) | (80.6 %) | (19.4 %) | (24.1 %) | |
| n = 211 | n = 87 | n = 124 | n = 170 | n = 41 | n = 67 | |
| IL8 (pg/mL)abc | 1.224 ± 1.387 | 0.763 ± 0.824 | 1.547 ± 1.598 | 1.020 ± 1.177 | 2.070 ± 1.826 | 0.566 ± 0.464 |
| MMP9 (ng/mL)abc | 0.485 ± 0.536 | 0.311 ± 0.261 | 0.607 ± 0.638 | 0.411 ± 0.434 | 0.792 ± 0.770 | 0.319 ± 0.366 |
| SERPINA1 (ng/mL)abc | 2.648 ± 2.538 | 1.891 ± 1.594 | 3.180 ± 2.920 | 2.312 ± 2.147 | 4.041 ± 3.444 | 1.061 ± 0.711 |
| ANG (pg/mL)abc | 2.133 ± 1.181 | 1.812 ± 0.928 | 2.358 ± 1.286 | 1.979 ± 1.037 | 2.770 ± 1.504 | 1.190 ± 0.543 |
| VEGF (pg/mL)abc | 1.852 ± 1.021 | 1.570 ± 0.610 | 2.050 ± 1.193 | 1.731 ± 0.897 | 2.352 ± 1.322 | 1.386 ± 0.395 |
| CA9 (pg/mL)abc | 0.770 ± 0.971 | 0.577 ± 0.480 | 0.905 ± 1.185 | 0.668 ± 0.805 | 1.190 ± 1.411 | 0.357 ± 0.242 |
| MMP10 (pg/mL)abc | 0.989 ± 1.625 | 0.626 ± 0.422 | 1.243 ± 2.055 | 0.814 ± 1.346 | 1.713 ± 2.353 | 0.517 ± 0.492 |
| APOE (pg/mL)abc | 0.639 ± 0.427 | 0.491 ± 0.307 | 0.744 ± 0.468 | 0.571 ± 0.373 | 0.923 ± 0.518 | 0.420 ± 0.177 |
| SERPINE1 (ng/mL)abc | 0.156 ± 0.181 | 0.096 ± 0.080 | 0.198 ± 0.217 | 0.125 ± 0.134 | 0.284 ± 0.273 | 0.056 ± 0.030 |
| SDC1 (pg/mL)a | 0.489 ± 0.140 | 0.468 ± 0.127 | 0.504 ± 0.147 | 0.478 ± 0.129 | 0.534 ± 0.172 | 0.331 ± 0.121 |
NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer
a P < 0.05 comparing total bladder cancer to total controls
b P < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer
c P < 0.05 comparing NMIBC to MIBC